Immunotoxins directed against malignant cells
AssigneeSecretary, Department of Health and Human Services
InventorsSusanna M. Rybak, Dianne L. Newton, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a Rana pipiens protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.
Claims34
A selective cytotoxic reagent comprising an one protein having measurable ribonucleolytic activity joined to an antibody directed against a surface marker expressed by a B cell.
A pharmaceutical composition comprising a selective cytotoxic reagent comprising an onc protein having measurable ribonucleolytic activity joined to an antibody directed against a cell surface marker expressed by a B cell together with a pharmaceutically acceptable carrier.
A method of killing malignant B cells comprising contacting cells to be killed with a selective cytotoxic reagent comprising an onc protein having measurable ribonucleolytic activity joined to an antibody directed against a cell surface marker on B cells.
A method of killing malignant cells bearing a CD74 cell surface marker comprising contacting cells to be killed with a selective cytotoxic reagent comprising an onc protein having measurable ribonucleolytic activity joined to an antibody directed against CD74.
Dependencies are inferred from the claim text.